Opening book details…
Can I read A Pilot, Randomized, Open‐label Trial Assessing Safety and Pharmakokinetic Parameters of Co‐administration of Rivastigmine with Risperidone in Dementia Patients with Behavioral Disturbances on EtoBox?
A Pilot, Randomized, Open‐label Trial Assessing Safety and Pharmakokinetic Parameters of Co‐administration of Rivastigmine with Risperidone in Dementia Patients with Behavioral Disturbances by Mark Weiser; Heschi H. Rotmensch; Amos D. Korczyn; Richard Hartman; Ana Cicin‐Sain; Ravi Anand is a Medicine article available to read on EtoBox.
What is A Pilot, Randomized, Open‐label Trial Assessing Safety and Pharmakokinetic Parameters of Co‐administration of Rivastigmine with Risperidone in Dementia Patients with Behavioral Disturbances about?
## Abstract ## Background The majority of patients with Alzheimer's disease (AD) or vascular dementia display, in addition to cognitive impairment, various degrees of behavioral disturbances. As the use of cholinesterase inhibitors for the treatment of cognitive impairment in dementia becomes widespread, many of these patients will be treated concomitantly with cholinesterase inhibitors and with anti‐psychotic drugs to ameliorate behavioral disturbances. Despite the widespread use of this combination in clinical practice, the safety and tolerability of such combination therapy has not been evaluated in controlled clinical trials. This pilot study examined the effects of addition of risperidone 0.5–2 mg/day to patients on rivastigmine 3–12 mg/day, and vice versa. ## Methods 65 patients suffering from AD, 10 from vascular dementia, and 15 from both were randomized to open label rivastigmine and risperidone, alone or in combination, for 20 weeks. Adverse events caused by co‐administration were assessed. ## Results No clinically relevant adverse interactions were observed. ## Conclusions These preliminary results indicate that rivastigmine and risperidone can be safely co‐administered.
Who reads A Pilot, Randomized, Open‐label Trial Assessing Safety and Pharmakokinetic Parameters of Co‐administration of Rivastigmine with Risperidone in Dementia Patients with Behavioral Disturbances?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Mark Weiser; Heschi H. Rotmensch; Amos D. Korczyn; Richard Hartman; Ana Cicin‐Sain; Ravi Anand
- Publisher
- John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley; Research Square (ISSN 0885-6230)
- Published
- 2002
- Language
- EN
- Field
- Medicine (Health Sciences)